AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Offsetting Humira's expected declines, AbbVie looks well-positioned with next-generation immunology drugs. In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy ...

On Friday, when AbbVie reported its quarterly earnings, the pharma giant jacked up its 2027 projected sales of Humira follow-ons Skyrizi and Rinvoq to a combined $31 billion. It is a $4 billion ...

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.